Adaptimmune Therapeutics-ADRADAPY
13F holders, Q1 2026 (March 31)1holders −9
0new positions
9sold out
$0.02avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Adaptimmune Therapeutics-ADR (ADAPY) in their 13F filings, down 9 from Q4 2025. 0 opened new positions and 9 sold out. The largest holder was Rhumbline Advisers ($72).
- Company
- Adaptimmune Therapeutics-ADR
- CUSIP
- 00653A107
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 9 | $80K |
All 13F filers, Q4 2025 → Q1 2026: 1,656,336 shares sold, net −1,656,336 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Rhumbline Advisers | 0.00% | No change | 3,661 | $72 |
"% of holder's portfolio" is ADAPY's weight in each manager's 13F, not the share of Adaptimmune Therapeutics-ADR the manager owns.